|
|

Home > Healthcare > Pharmaceutical > Drug Discovery
Regulatory Hurdles in European Drug Discovery
 |
| Published Date:
January 2006
Published By:
Frost & Sullivan
Page Count:
82
Order Code:
R1-4610
|
|
|
1. Regulatory Hurdles in European Drug Discovery 1. Overview 1. Overview 2. Research Scope & Methodology 1. Research Scope & Methodology 3. Key Definitions and Abbreviations 1. Key Definitions and Abbreviations 4. Introduction 1. Introduction 5. Overview of EC Directives 1. Overview of EC Directives 6. European Authorisation Procedure 1. European Authorisation Procedure 7. Regulatory Policy 1. Regulatory Policy 8. State Members of the European Union 1. State Members of the European Union 9. Applicants and Other European Countries 1. Applicants and Other European Countries 10. Regulatory Challenges 1. Regulatory Challenges 11. Regulatory Hurdles in Austrian Drug Discovery 1. Regulatory Hurdles in Austrian Drug Discovery 12. Regulatory Hurdles in Belgium Drug Discovery 1. Regulatory Hurdles in Belgium Drug Discovery 13. Regulatory Hurdles in Czech Republic Drug Discovery 1. Regulatory Hurdles in Czech Republic Drug Discovery 14. Regulatory Hurdles in Danish Drug Discovery 1. Regulatory Hurdles in Danish Drug Discovery 15. Regulatory Hurdles in Finnish Drug Discovery 1. Regulatory Hurdles in Finnish Drug Discovery 16. Regulatory Hurdles in French Drug Discovery 1. Regulatory Hurdles in French Drug Discovery 17. Regulatory Hurdles in German Drug Discovery 1. Regulatory Hurdles in German Drug Discovery 18. Regulatory Hurdles in Greek Drug Discovery 1. Regulatory Hurdles in Greek Drug Discovery 19. Regulatory Hurdles in Hungarian Drug Discovery 1. Regulatory Hurdles in Hungarian Drug Discovery 20. Regulatory Hurdles in Italian Drug Discovery 1. Regulatory Hurdles in Italian Drug Discovery 21. Regulatory Hurdles in Polish Drug Discovery 1. Regulatory Hurdles in Polish Drug Discovery 22. Regulatory Hurdles in Portuguese Drug Discovery 1. Regulatory Hurdles in Portuguese Drug Discovery 23. Regulatory Hurdles in Slovakian Drug Discovery 1. Regulatory Hurdles in Slovakian Drug Discovery 24. Regulatory Hurdles in Spanish Drug Discovery 1. Regulatory Hurdles in Spanish Drug Discovery 25. Regulatory Hurdles in Swedish Drug Discovery 1. Regulatory Hurdles in Swedish Drug Discovery 26. Regulatory Hurdles in the United Kingdom Drug Discovery 1. Regulatory Hurdles in the United Kingdom Drug Discovery 27. Conclusion 1. The Future 28. Decision Support Databases 1. Decision Support Databases |
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|